# P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease

> **NCT06489340** · PHASE2 · WITHDRAWN · sponsor: **ZyVersa Therapeutics, Inc.**

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** 2HPβCD

## Key facts

- **NCT ID:** NCT06489340
- **Lead sponsor:** ZyVersa Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06-11
- **Primary completion:** 2026-08-11
- **Final completion:** 2026-08-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn due to patient enrollment challenges
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06489340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06489340, "P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06489340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*